Day 1 Recap: AAD 2025

Image Credit: © Kevin Ruck - stock.adobe.com

To stay informed with the latest conference insights, subscribe to receive our eNewsletters.

Almirall Showcases Therapeutic Innovations at AAD 2025

Kicking off the first day of AAD, Almirall showcased its latest dermatology research through five scientific posters, highlighting new data on tirbanibulin, a topical treatment for actinic keratosis (AK), and early-stage clinical results for LAD191, a novel monoclonal antibody targeting IL-1RAP. The findings reinforce tirbanibulin’s effectiveness, high patient satisfaction, and favorable safety profile, emphasizing the importance of patient-centered care in AK treatment. Additionally, phase I data on LAD191 support its potential as an innovative therapy for immune-mediated skin conditions.

Adewole Adamson, MD, MPP: Getting Ready to Tackle Dermatology's Key Challenges Issues at AAD 2025

Adewole (Ade) Adamson, MD, MPP, an assistant professor of dermatology at Dell Medical School, University of Texas at Austin, is set to participate in 2 key sessions at this years meeting. Today, he took part in "Approach to Melanoma Diagnosis" and "The 2025 Debates: Controversies in Dermatology," both addressing critical issues in the field.

As the director of the Melanoma and Pigmented Lesion Clinic at Dell Seton Medical Center, Adamson emphasized the value of tackling controversies in dermatology, stating that these discussions are opportunities for learning and progress. His sessions will focus on improving melanoma diagnostics and treatment strategies, particularly for high-risk patients. Adamson highlighted the AAD as a platform for engaging in rigorous dialogue with peers, ultimately driving advancements that enhance patient outcomes.

Exploring the IBD-Dermatology Connection

Alexandra P. Charrow, MD, FAAD, highlighted the intricate connections between dermatological conditions and systemic diseases, particularly inflammatory bowel disease (IBD) and hidradenitis suppurativa (HS). As director of multiple dermatology programs at Harvard Medical School, Charrow emphasizes the shared pathways linking IBD and skin disorders, including the impact of Crohn’s disease on dermatologic health. Her research focuses on metastatic cutaneous Crohn’s, where inflammation occurs in non-contiguous skin areas. Charrow’s work aims to refine diagnostic criteria and deepen understanding of these complex interactions, ultimately improving patient care.

AAD Announces Newly Appointed Leadership Officers

This year's annual meeting began with the announcement of new leadership, including the appointment of Susan C. Taylor, MD, FAAD, as AAD president. A distinguished dermatologist and professor at the University of Pennsylvania, Taylor is the 6th woman and first African American clinician to hold this position. Her leadership will focus on improving patient access to care and expanding resources for AAD members. Joining her are vice president Kevin D. Cooper, MD, FAAD; secretary-treasurer Keyvan Nouri, MD, MBA, FAAD; and assistant secretary-treasurer Sabra Sullivan, MD, PhD, FAAD; along with 4 newly appointed board members. This leadership team aims to advance dermatologic care, research, and advocacy efforts within the field.

Tattoo Ink Risks, MultiFrax Laser, and the Impact of GLP-1 Medications on Skin Health

Jeanine Downie, MD, FAAD, shared insights on emerging dermatologic innovations and safety concerns in her session, "Pearls From the Masters of Dermatologic Surgery." Key topics included tattoo ink safety, with concerns over contamination and carcinogenic components, and the introduction of MultiFrax laser technology for skin resurfacing. She also highlighted PRX, a topical collagen biostimulator now available in the US, which offers skin rejuvenation without hyperpigmentation risks. Additional discussions covered the potential of salmon sperm polynucleotides for skin regeneration, the role of sirtuins in longevity, and managing aesthetic concerns linked to GLP-1 medications.

Early-Career Tips for Attending AAD 2025

Finally, Raj Chovatiya, MD, PhD, MSCI, shared insights on navigating the conference and staying updated on the latest advancements in dermatology. Presenting on inflammatory disorders, including atopic dermatitis, psoriasis, and hidradenitis suppurativa, Chovatiya emphasized the importance of strategic session selection for early-career clinicians. He advised prioritizing key topics over trying to attend everything, highlighting the rapid evolution of dermatologic treatments. With breakthroughs emerging annually, he noted that even major clinical trials might not make the late-breaking sessions due to the volume of new data. Encouraging a balanced approach to education and networking, Chovatiya underscored the significance of staying informed on innovations that will shape the future of patient care.

Stay tuned for more expert insights, clinical research, and late-breaking data from AAD 2025.